Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

Canada NewsWire November 24, 2020

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

PR Newswire November 16, 2020

MindMed Announces Q3 2020 Financial Results;

Canada NewsWire November 13, 2020

MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

Canada NewsWire November 2, 2020

MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

Canada NewsWire October 30, 2020

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire October 27, 2020

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire October 16, 2020

MindMed Announces $25 Million Bought Deal Public Offering

Canada NewsWire October 9, 2020

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

Canada NewsWire October 5, 2020

MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

Canada NewsWire September 24, 2020

MindMed Confirms No Material Change

Canada NewsWire September 23, 2020

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

Canada NewsWire September 21, 2020

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Canada NewsWire August 25, 2020

/C O R R E C T I O N -- Mind Medicine (MindMed) Inc./

Canada NewsWire August 20, 2020

60 Minutes: Psychedelics Could Help People with Addiction and Anxiety

Livemoney August 18, 2020

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

PR Newswire August 14, 2020

MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

Canada NewsWire August 13, 2020

This Landmark Decision is a Major Game Changer for Companies Focused on Psylocybin

Livemoney August 10, 2020

Venture Company Investor Presentations Now Available for On-Demand Viewing

Canada NewsWire August 10, 2020

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Canada NewsWire August 6, 2020